 Erik Oleson
Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dopamine | 24 | 2021 | 234 | 6.680 |
Why?
| | Nucleus Accumbens | 21 | 2020 | 123 | 5.400 |
Why?
| | Reward | 12 | 2021 | 211 | 2.440 |
Why?
| | Avoidance Learning | 6 | 2020 | 63 | 2.420 |
Why?
| | Endocannabinoids | 10 | 2021 | 36 | 2.410 |
Why?
| | Behavior, Animal | 12 | 2018 | 446 | 2.310 |
Why?
| | Cocaine | 12 | 2013 | 153 | 2.010 |
Why?
| | Heroin | 2 | 2020 | 24 | 1.410 |
Why?
| | Cannabinoids | 3 | 2021 | 115 | 1.370 |
Why?
| | Benzoxazines | 3 | 2020 | 27 | 1.330 |
Why?
| | Motivation | 6 | 2020 | 486 | 1.320 |
Why?
| | Naphthalenes | 3 | 2020 | 37 | 1.310 |
Why?
| | Cannabinoid Receptor Agonists | 5 | 2021 | 30 | 1.300 |
Why?
| | Morpholines | 3 | 2020 | 102 | 1.270 |
Why?
| | Dopamine Antagonists | 2 | 2020 | 22 | 1.070 |
Why?
| | Rats | 23 | 2020 | 4829 | 1.060 |
Why?
| | Self Administration | 8 | 2013 | 122 | 1.030 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 770 | 0.860 |
Why?
| | Arachidonic Acids | 4 | 2020 | 56 | 0.780 |
Why?
| | Economics, Behavioral | 2 | 2018 | 9 | 0.760 |
Why?
| | Substance Withdrawal Syndrome | 3 | 2021 | 159 | 0.750 |
Why?
| | Biological Psychiatry | 1 | 2021 | 2 | 0.740 |
Why?
| | Neuropharmacology | 1 | 2021 | 5 | 0.740 |
Why?
| | Psychopharmacology | 1 | 2021 | 7 | 0.730 |
Why?
| | Rats, Long-Evans | 6 | 2020 | 96 | 0.720 |
Why?
| | Cocaine-Related Disorders | 6 | 2012 | 108 | 0.700 |
Why?
| | Drug Tolerance | 1 | 2020 | 77 | 0.700 |
Why?
| | Dopamine Uptake Inhibitors | 2 | 2012 | 54 | 0.680 |
Why?
| | Animals | 36 | 2021 | 31162 | 0.680 |
Why?
| | Central Nervous System Stimulants | 2 | 2012 | 140 | 0.670 |
Why?
| | Conditioning, Operant | 6 | 2013 | 97 | 0.650 |
Why?
| | Diazepam | 2 | 2018 | 26 | 0.610 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2020 | 1822 | 0.570 |
Why?
| | Buprenorphine | 1 | 2020 | 133 | 0.560 |
Why?
| | Receptor, Cannabinoid, CB1 | 3 | 2013 | 28 | 0.530 |
Why?
| | Marijuana Abuse | 3 | 2021 | 207 | 0.510 |
Why?
| | Rats, Sprague-Dawley | 12 | 2018 | 2139 | 0.480 |
Why?
| | Neurochemistry | 1 | 2014 | 5 | 0.480 |
Why?
| | Reinforcement Schedule | 6 | 2013 | 29 | 0.480 |
Why?
| | Ventral Tegmental Area | 2 | 2013 | 45 | 0.480 |
Why?
| | Escape Reaction | 1 | 2014 | 58 | 0.470 |
Why?
| | Consummatory Behavior | 2 | 2010 | 5 | 0.440 |
Why?
| | Biological Clocks | 1 | 2013 | 37 | 0.440 |
Why?
| | Dronabinol | 3 | 2021 | 118 | 0.430 |
Why?
| | Neurotransmitter Agents | 1 | 2013 | 74 | 0.420 |
Why?
| | Punishment | 1 | 2012 | 20 | 0.410 |
Why?
| | Fear | 3 | 2018 | 292 | 0.400 |
Why?
| | Benztropine | 1 | 2012 | 2 | 0.400 |
Why?
| | Histamine H1 Antagonists | 1 | 2012 | 28 | 0.390 |
Why?
| | Cannabinoid Receptor Modulators | 1 | 2012 | 6 | 0.390 |
Why?
| | Glycerides | 3 | 2020 | 14 | 0.390 |
Why?
| | Piperidines | 2 | 2013 | 159 | 0.380 |
Why?
| | Brain | 4 | 2021 | 2309 | 0.380 |
Why?
| | GABA-B Receptor Agonists | 1 | 2010 | 3 | 0.360 |
Why?
| | Appetitive Behavior | 1 | 2010 | 8 | 0.360 |
Why?
| | Dopaminergic Neurons | 3 | 2018 | 43 | 0.340 |
Why?
| | Corpus Striatum | 2 | 2018 | 125 | 0.340 |
Why?
| | Male | 27 | 2020 | 55112 | 0.330 |
Why?
| | Analgesics | 2 | 2020 | 156 | 0.320 |
Why?
| | Motor Activity | 3 | 2013 | 623 | 0.310 |
Why?
| | Cues | 5 | 2018 | 303 | 0.250 |
Why?
| | Electrochemical Techniques | 2 | 2018 | 45 | 0.230 |
Why?
| | Models, Animal | 2 | 2018 | 337 | 0.220 |
Why?
| | Substance-Related Disorders | 1 | 2012 | 931 | 0.220 |
Why?
| | Carrier Proteins | 4 | 2006 | 685 | 0.190 |
Why?
| | Time Factors | 5 | 2017 | 6032 | 0.190 |
Why?
| | Crime Victims | 1 | 2022 | 80 | 0.180 |
Why?
| | Mice, Inbred C57BL | 6 | 2013 | 4617 | 0.180 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 712 | 0.180 |
Why?
| | Receptors, Opioid, mu | 1 | 2020 | 50 | 0.170 |
Why?
| | Extinction, Psychological | 2 | 2018 | 78 | 0.170 |
Why?
| | Mice | 10 | 2021 | 14679 | 0.170 |
Why?
| | Optogenetics | 2 | 2018 | 95 | 0.170 |
Why?
| | Administration, Intravenous | 1 | 2020 | 122 | 0.170 |
Why?
| | Sexual and Gender Minorities | 1 | 2022 | 140 | 0.170 |
Why?
| | Sex Offenses | 1 | 2022 | 148 | 0.170 |
Why?
| | Drug Combinations | 1 | 2020 | 285 | 0.160 |
Why?
| | N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2018 | 10 | 0.160 |
Why?
| | Serotonin Agents | 1 | 2018 | 8 | 0.160 |
Why?
| | GABA-A Receptor Agonists | 1 | 2018 | 9 | 0.160 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2018 | 14 | 0.160 |
Why?
| | Memory Consolidation | 1 | 2018 | 11 | 0.160 |
Why?
| | Pain Measurement | 1 | 2020 | 440 | 0.150 |
Why?
| | Receptors, GABA-A | 1 | 2018 | 81 | 0.150 |
Why?
| | Flumazenil | 1 | 2017 | 6 | 0.150 |
Why?
| | Synaptic Transmission | 2 | 2021 | 227 | 0.130 |
Why?
| | Central Nervous System Depressants | 2 | 2007 | 80 | 0.130 |
Why?
| | Neurons | 2 | 2014 | 1261 | 0.130 |
Why?
| | Geriatrics | 1 | 2015 | 69 | 0.120 |
Why?
| | Clinical Clerkship | 1 | 2015 | 72 | 0.120 |
Why?
| | Polyunsaturated Alkamides | 1 | 2013 | 7 | 0.110 |
Why?
| | Neuronal Plasticity | 2 | 2006 | 207 | 0.110 |
Why?
| | Exploratory Behavior | 2 | 2012 | 79 | 0.110 |
Why?
| | Age Factors | 1 | 2020 | 2875 | 0.110 |
Why?
| | Education, Medical, Undergraduate | 1 | 2015 | 158 | 0.110 |
Why?
| | Mental Disorders | 1 | 2021 | 884 | 0.110 |
Why?
| | Drug-Seeking Behavior | 1 | 2013 | 22 | 0.100 |
Why?
| | Impulsive Behavior | 1 | 2013 | 110 | 0.100 |
Why?
| | Task Performance and Analysis | 1 | 2013 | 160 | 0.100 |
Why?
| | Drug and Narcotic Control | 1 | 2012 | 29 | 0.100 |
Why?
| | Spatial Behavior | 1 | 2012 | 20 | 0.100 |
Why?
| | Ethanol | 2 | 2007 | 532 | 0.100 |
Why?
| | Action Potentials | 1 | 2014 | 402 | 0.100 |
Why?
| | Psychomotor Agitation | 1 | 2012 | 65 | 0.090 |
Why?
| | Behavior, Addictive | 1 | 2012 | 80 | 0.090 |
Why?
| | Humans | 9 | 2022 | 113531 | 0.090 |
Why?
| | Baclofen | 1 | 2010 | 10 | 0.090 |
Why?
| | Forecasting | 1 | 2012 | 329 | 0.090 |
Why?
| | Haloperidol | 1 | 2010 | 35 | 0.090 |
Why?
| | Electroencephalography | 1 | 2012 | 332 | 0.090 |
Why?
| | Fluoxetine | 1 | 2010 | 46 | 0.090 |
Why?
| | Databases, Factual | 1 | 2014 | 1127 | 0.080 |
Why?
| | Mesencephalon | 1 | 2009 | 56 | 0.080 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 368 | 0.080 |
Why?
| | Nerve Net | 1 | 2012 | 227 | 0.080 |
Why?
| | Limbic System | 1 | 2009 | 43 | 0.080 |
Why?
| | Neuropeptides | 1 | 2009 | 63 | 0.080 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 924 | 0.080 |
Why?
| | Kinetics | 1 | 2012 | 1528 | 0.080 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2008 | 39 | 0.080 |
Why?
| | Injections, Intravenous | 1 | 2008 | 195 | 0.080 |
Why?
| | Commerce | 1 | 2008 | 61 | 0.070 |
Why?
| | Analysis of Variance | 1 | 2010 | 1208 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2009 | 382 | 0.070 |
Why?
| | Glutamic Acid | 2 | 2006 | 207 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2010 | 505 | 0.070 |
Why?
| | Signal Transduction | 3 | 2021 | 4439 | 0.070 |
Why?
| | Homer Scaffolding Proteins | 4 | 2006 | 5 | 0.060 |
Why?
| | Models, Biological | 2 | 2012 | 1589 | 0.060 |
Why?
| | Anesthetics, Local | 1 | 2006 | 81 | 0.060 |
Why?
| | Maze Learning | 1 | 2005 | 86 | 0.060 |
Why?
| | Frontal Lobe | 1 | 2005 | 140 | 0.060 |
Why?
| | Psychomotor Performance | 1 | 2005 | 286 | 0.050 |
Why?
| | Prefrontal Cortex | 1 | 2005 | 262 | 0.050 |
Why?
| | Memory | 2 | 2018 | 211 | 0.050 |
Why?
| | Algorithms | 1 | 2008 | 1462 | 0.050 |
Why?
| | Survivors | 1 | 2022 | 414 | 0.040 |
Why?
| | GABA Modulators | 1 | 2018 | 7 | 0.040 |
Why?
| | Organ Culture Techniques | 1 | 2018 | 140 | 0.040 |
Why?
| | Microdialysis | 2 | 2009 | 49 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2293 | 0.030 |
Why?
| | Mice, Knockout | 3 | 2005 | 2523 | 0.030 |
Why?
| | Protein Isoforms | 2 | 2006 | 324 | 0.030 |
Why?
| | Goals | 1 | 2015 | 147 | 0.030 |
Why?
| | Cannabinoid Receptor Antagonists | 1 | 2013 | 1 | 0.030 |
Why?
| | Gene Deletion | 2 | 2005 | 351 | 0.030 |
Why?
| | Schizophrenia | 2 | 2005 | 409 | 0.020 |
Why?
| | Pyrazoles | 1 | 2013 | 361 | 0.020 |
Why?
| | Orexin Receptors | 1 | 2009 | 3 | 0.020 |
Why?
| | Orexins | 1 | 2009 | 3 | 0.020 |
Why?
| | Receptors, Neuropeptide | 1 | 2009 | 11 | 0.020 |
Why?
| | Naphthyridines | 1 | 2009 | 16 | 0.020 |
Why?
| | Benzoxazoles | 1 | 2009 | 16 | 0.020 |
Why?
| | Electrochemistry | 1 | 2009 | 77 | 0.020 |
Why?
| | Urea | 1 | 2009 | 65 | 0.020 |
Why?
| | Random Allocation | 1 | 2009 | 326 | 0.020 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2009 | 182 | 0.020 |
Why?
| | Caudate Nucleus | 1 | 2007 | 14 | 0.020 |
Why?
| | Putamen | 1 | 2007 | 14 | 0.020 |
Why?
| | Volatilization | 1 | 2007 | 47 | 0.020 |
Why?
| | Receptors, Dopamine D2 | 1 | 2007 | 85 | 0.020 |
Why?
| | Cannabis | 1 | 2012 | 382 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2007 | 633 | 0.020 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2005 | 86 | 0.020 |
Why?
| | Reflex | 1 | 2005 | 63 | 0.020 |
Why?
| | Drug Synergism | 1 | 2005 | 312 | 0.010 |
Why?
| | Down-Regulation | 1 | 2007 | 593 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2006 | 463 | 0.010 |
Why?
| | Neural Inhibition | 1 | 2005 | 138 | 0.010 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2005 | 177 | 0.010 |
Why?
| | Piperazines | 1 | 2005 | 309 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2005 | 1136 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2006 | 1214 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2005 | 1065 | 0.010 |
Why?
| | Alcohol Drinking | 1 | 2005 | 651 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2005 | 1856 | 0.010 |
Why?
| | Phenotype | 1 | 2005 | 2754 | 0.010 |
Why?
| | Female | 3 | 2005 | 59115 | 0.010 |
Why?
|
|
Oleson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|